Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984350 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL1626250 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL9911164 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL16259947 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL12150843 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL1626249 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL1627641 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL1627640 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL11540698 | 0.89 | CA2 (0.48) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL20068297 | 0.89 | CA2 (0.48) | CA2CA12CA1CA9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3043803-B1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND THEIR USES | UNIV EMORY (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | CA2 4467/4885CA12 3952/4885CA1 4734/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | CA2 3698/4885CA12 3724/4885CA1 4823/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | CA2 4570/4885CA12 4098/4885CA1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.